SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(De Fine Licht Sofie)
 

Sökning: WFRF:(De Fine Licht Sofie) > Short-acting β2 -ag...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005901naa a2200793 4500
001oai:gup.ub.gu.se/320612
003SwePub
008240528s2022 | |||||||||||000 ||eng|
009oai:DiVA.org:uu-492866
009oai:lup.lub.lu.se:e5557362-531a-4cd1-be14-de72a46cad55
009oai:prod.swepub.kib.ki.se:151807007
0247 a https://gup.ub.gu.se/publication/3206122 URI
0247 a https://doi.org/10.1111/pai.138852 DOI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4928662 URI
0247 a https://lup.lub.lu.se/record/e5557362-531a-4cd1-be14-de72a46cad552 URI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1518070072 URI
040 a (SwePub)gud (SwePub)uud (SwePub)lud (SwePub)ki
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Melén, Eriku Karolinska Institutet,Karolinska Institute,Sachs’ Children and Youth Hospital4 aut
2451 0a Short-acting β2 -agonist use and asthma exacerbations in Swedish children: A SABINA Junior study.
264 c 2022-11-21
264 1b Wiley,c 2022
520 a In adults and adolescents with asthma, use of ≥3 short-acting β2 -agonist (SABA) canisters/year is associated with increased exacerbation risk. Whether this association is present in younger children remains unknown. In this SABA use IN Asthma (SABINA) Junior study, we assessed the association of SABA collection with exacerbation risk in the general Swedish pediatric asthma population.This population-based cohort study utilized linked data from the Swedish national healthcare registries involving patients with asthma (<18years) treated in secondary care between 2006-2015. Exacerbation risk, by baseline SABA collection (0-2 vs. ≥3 canisters, further examined as ordinal/continuous variable) and stratified on comorbid atopic disease (allergic rhinitis, dermatitis and eczema, and food/other allergies), was assessed for 1-year follow-up using negative binomial regression.Of 219,561 patients assessed, 45.4%, 31.7%, and 26.5% of patients aged 0-5, 6-11, and 12-17years, respectively, collected ≥3 SABA canisters during the baseline year (high use). Collection of ≥3 SABA canisters (vs. 0-2) was associated with increased exacerbation risk during follow-up (incidence rate ratios [95% confidence interval]: 1.35 [1.29-1.42], 1.22 [1.15-1.29], and 1.26 [1.19-1.34] for 0-5-, 6-11-, and 12-17-year-olds, respectively); the association persisted with SABA as a continuous variable and was stronger among patients without atopic diseases (32%-44% increased risk versus. 14%-21% for those with atopic disease across groups).High SABA use was associated with increased asthma exacerbation risk in children, particularly in those without comorbid atopic diseases, emphasizing the need for asthma medication reviews and reformative initiatives by caregivers and healthcare providers on SABA use.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Hälsovetenskapx Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi0 (SwePub)303022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Health Sciencesx Public Health, Global Health, Social Medicine and Epidemiology0 (SwePub)303022 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Lungmedicin och allergi0 (SwePub)302192 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Respiratory Medicine and Allergy0 (SwePub)302192 hsv//eng
653 a Adult
653 a Adolescent
653 a Humans
653 a Child
653 a Cohort Studies
653 a Sweden
653 a epidemiology
653 a Asthma
653 a drug therapy
653 a epidemiology
653 a Rhinitis
653 a Allergic
653 a SABINA junior study
653 a asthma
653 a children
653 a exacerbations
653 a pediatric
653 a SABINA junior study
653 a short-acting β-agonists
7001 a Nwaru, Bright I,d 1978u University of Gothenburg,Gothenburg University,Göteborgs universitet,Krefting Research Centre4 aut0 (Swepub:gu)xnwabr
7001 a Wiklund, Fredriku Statisticon4 aut0 (Swepub:lu)med-fwd
7001 a de Fine Licht, Sofieu AstraZeneca, Sweden4 aut
7001 a Telg, Gunillau AstraZeneca, Sweden4 aut
7001 a Maslova, Ekaterinau AstraZeneca, UK4 aut
7001 a van der Valk, Ralf J Pu AstraZeneca, UK4 aut
7001 a Tran, Trung Nu AstraZeneca, UK4 aut
7001 a Ekström, Magnusu Lund University,Lunds universitet,Palliativt Utvecklingscentrum,Forskargrupper vid Lunds universitet,Andfåddhet och kronisk andningssvikt,The Institute for Palliative Care,Lund University Research Groups,Breathlessness and chronic respiratory failure4 aut0 (Swepub:lu)med-mue
7001 a Janson, Christeru Uppsala University,Uppsala universitet,Lung- allergi- och sömnforskning4 aut0 (Swepub:uu)chrisjn
7102 a Karolinska Instituteb Sachs’ Children and Youth Hospital4 org
7730 t Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunologyd : Wileyg 33:11q 33:11x 1399-3038x 0905-6157
7730 t Pediatric Allergy and Immunologyd : Wileyg 33:11q 33:11x 0905-6157
8564 u https://doi.org/10.1111/pai.13885y Fulltext
8564 u https://uu.diva-portal.org/smash/get/diva2:1725325/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 u http://dx.doi.org/10.1111/pai.13885x freey FULLTEXT
8564 8u https://gup.ub.gu.se/publication/320612
8564 8u https://doi.org/10.1111/pai.13885
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-492866
8564 8u https://lup.lub.lu.se/record/e5557362-531a-4cd1-be14-de72a46cad55
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:151807007

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy